Partnering tabs - Core Therapeutic Areas " >Partnering tabs - Core Therapeutic Areas

Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms. We have arguably the richest and broadest pipeline in the industry with more than 65 New Molecular Entities in development. Please select your therapy area of interest to connect to one of our specialist partnering professionals.

Looking for truly differentiating first or best-in-class treatments in:

  • Heart Failure, Hypertension and Atrial Fibrillation
  • Atherosclerosis and multiple CV risk factor management
  • Metabolic (including Obesity)
Avi Spier portrait

 

Avi Spier

Contact

Thierry Droz-Georget

Thierry Droz-Georget

Contact

Looking for truly differentiating first or best-in-class treatments in:

  • Rheumatology
  • Dermatology
  • Disease modifying Osteoarthritis
  • Nucleic acid sensing and Inflammasome
  • Tolerance induction
  • Allergy
Enrico Funhoff portrait

Rico Funhoff

Contact

 

Dominic Ehrismann portrait

Dominic Ehrismann

Contact

Looking for truly differentiating first or best-in-class treatments in:

  • Neurodegeneration and Neuroinflammation 
  • Pediatric Neurological Diseases 
  • Psychiatry
Chi-Chi Zhu

Chi-Chi Zhu

Contact

Looking for truly differentiating first or best-in-class treatments in:

  • Around Radioligand Therapies (RLT), including novel targets and advanced programs complementary to current pipeline and disease focus, isotopes and chelators for tumor specific RLT delivery
  • Targeted Therapies. Novel targets complementary to pipeline / portfolio, addressing unmet needs in breast, lung, prostate, CRC, and pancreatic malignancies
  • Immuno-oncology. Novel mechanisms complementary to anti-PD-1 or addressing unmet needs in breast, lung, CRC, prostate, and pancreatic malignancies
Reza Mazhari portrait

Reza Mazhari

Contact

Looking for truly differentiating first or best-in-class treatments:

  • Targeted Therapies as well as
  • Immuno-oncology based approaches with novel mechanisms that are complementary to our internal portfolio and pipeline addressing unmet needs in heme malignancies
  • Celle & Gene. Novel T cell-based cell therapies to expand CART portfolio including solid tumors and leverage internal T-ChargeTM platform in deal-making. Advance from ex vivo HSC and CART therapy to in vivo gene therapy
Markus Werner portrait

Markus Werner

Contact

Other Areas - Partnering tab " >Other Areas - Partnering tab

Seeking transformative approaches to address genetic disease

Blue icon of a business woman

Elizabeth Leshen

Contact

Ophthalmology

Seeking to develop and deliver life-changing medicines for diseases and conditions from front to back of the eye, enabled by data, transformative technologies, and partnerships.

Chris Adams

Chris Adams

Contact


Renal

Interested in disease modifying treatments and renal indications with high unmet need.

Andreas Sailer

Andreas Sailer

Contact


Respiratory

We are looking for partners to expand our portfolio with innovative and potentially transformative agents with a primary focus in subspeciality respiratory (e.g. IPF, sarcoidosis, bronchiectasis), life threatening hospital conditions (e.g. ARDS, BPD).

Andreas Sailer

Andreas Sailer

Contact

We accept that innovation happens outside of areas of interest- we are still prepared to discuss transformational areas we may have missed. We have a special team for you to talk with.

Andreas Sailer

Andreas Sailer

Contact

Platform Collaborations - Partnering tab " >Platform Collaborations - Partnering tab

Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.

Guy Greiveldinger portrait

Guy Greiveldinger

Contact

 

Frank Dieterle

Frank Dieterle

Contact

Our focus on 2+3 technology platforms.

Chemistry

Avi Spier portrait

Avi Spier

Contact


Biologics

Gianfranco de Pascale

Gianfranco de Pascale

Contact


xRNA

Gianfranco de Pascale

Gianfranco de Pascale

Contact


Cell and Gene in Oncology

Markus Werner portrait

Markus Werner

Contact


Radioligand Therapy

Reza Mazhari portrait

Reza Mazhari

Contact

Chemical Biology and Therapeutics (CBT).

At CBT, we strive to innovate the science of therapeutics through a dynamic culture of enabling partnerships. Through a variety of technologies and talents, we translate exceptional science into medical innovation.

Cynthia Hong

Cynthia Hong

Contact

Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including tropical infectious diseases.


Charles Bailey

 

Charles Bailey

Contact me for partnerships.

Contact